After years of careful investigation, researchers working on the Micro Booster Neutrino Experiment (MicroBooNE) have determined that a long-hypothesized particle known as the sterile neutrino does not exist. This proposed particle had been widely…
Washington, D.C., Jan. 12, 2026 — FTI Consulting, Inc. (NYSE: FCN) today announced the expansion of its transactions, shareholder activism and issues management capabilities with the appointments of Dan Scorpio and Heather Wilson as Senior Managing Directors within the firm’s Strategic Communications segment.
“Guiding a transaction from announcement through close has never been more challenging with complex, intertwined stakeholder risks that pose meaningful threats to successful close and value realization,” said Pat Tucker, Americas Head of M&A and Activism for the Strategic Communications segment at FTI Consulting. “The dedicated, multi-disciplinary M&A team we’ve assembled is unique and enables our clients to understand, anticipate and mitigate risks to capture transaction value. The addition of Heather and Dan, and geographic expansion in the Midwest and West Coast, is an important milestone for our transaction and overall event-driven communications offering that will have an immediate impact for our clients.”
Mr. Scorpio, who is based in Chicago, has more than a decade of experience leading high-profile M&A and reputational engagements for Fortune 500 companies, private equity and family businesses such as T-Mobile, Keurig Dr Pepper, IFF and Pritzker Private Capital, as well as Medline on its 2025 IPO, the largest globally since 2021. In his role, Mr. Scorpio will advise clients on M&A transactions, shareholder activism defense and financial communications issues.
Prior to joining FTI Consulting, Mr. Scorpio was a Managing Director and Head of the M&A and Activism practice at H/Advisors Abernathy, where he provided strategic communications, stakeholder engagement and reputation management counsel to executive leadership teams and boards of directors. He has presented at the Garrett Institute and Corporate Counsel Institute and at industry forums hosted by National Investor Relations Institute, National Association of Corporate Directors and the Society for Corporate Governance.
Commenting on his appointment, Mr. Scorpio said, “I am thrilled to join FTI Consulting and its rapidly growing M&A and Activism team. FTI Consulting’s differentiated offering is resonating in today’s dynamic marketplace, as clients are demanding experienced counsel, data-driven insights and highly tailored strategic execution through the moments that matter most. As the M&A market gains momentum in an increasingly complex global geopolitical environment, it’s clear to me that the integrated resources of FTI Consulting are best suited to solve companies’ most pressing challenges and partner with clients to achieve their business goals.”
Ms. Wilson, who is based in Los Angeles, has deep expertise in transactions, crisis and issues management. She has worked across a range of industries, including for organizations such as IBM, HP, AbbVie, Mattel, the state of California and Goop, and for venture capital and private equity funds on issues including crisis response, high-profile litigation, transaction communications and investor relations, and public affairs. She is a frequent public speaker on crisis management and special situations.
At FTI Consulting, Ms. Wilson will advise clients around transactions and crisis situations and bolster the firm’s presence on the West Coast. Prior to joining FTI Consulting, Ms. Wilson was the Senior Vice President and Chief Marketing and Communications Officer at AccentCare, a national provider of home health services, where she led all communications, crisis and issues management, digital and brand marketing. Earlier in her career, she was a journalist at CBS Marketwatch, Fox News and CNBC.
Commenting on her appointment, Ms. Wilson said, “FTI Consulting has a world-class strategic communications team with deep and broad expertise to handle our clients’ unique needs through any crisis or deal lifecycle. I’m excited to join this integrated team and expand our footprint in the Golden State.”
FTI Consulting’s integrated transaction communications offering supports clients in realizing deal success by delivering investor support and approval, mitigating political risk for regulatory clearance and setting clients up for integration success. The team taps into the firm’s global expertise across corporate reputation, investor relations, public affairs, people and transformation and digital strategy. This work is complemented by FTI Consulting’s broader M&A and Activism services, including merger integration, business transformation, media relations, proxy advisory, investor engagement, ESG strategy and strategic advisory work for chief financial officers.
About
555 12th Street NW
+1.202.312.9100
Investor Contact:
+1.617.747.1791
mollie.hawkes@fticonsulting.com
Media Contact:
+1.617.480.7402
samantha.ford@fticonsulting.com
Source: FTI Consulting, Inc.
SAVE $20: As of Jan. 12, the Hisense Class A4 TV is on sale for $99.99 at Amazon. That’s a 17% saving on the list price.
SAVE $100: As of Jan. 12, the Google Pixel 9a is on sale for $399 at Amazon. That’s a 20% discount on the list price.
…
The Punjab government has launched a program to provide free AIDS screening, essential diagnostic tests, and complete treatment through special clinics established at district and tehsil levels.
Medical research has confirmed that AIDS,…
The Data Protection Commission (DPC) is owed more than €4 billion in fines that have not been collected or are subject to legal challenge.
The DPC hit companies – including firms in Big Tech – with more than €530m in…
A robotic ocean float has collected the first-ever continuous measurements from beneath floating ice shelves in East Antarctica, shedding new light on how ocean heat may influence the stability of some of…
Our portfolio companies are building technology that rearchitects how we build, work, and thrive together. But transformative technology only matters if it reaches the right people and institutions. Our strategic partners offer decades of domain expertise and operational muscle to help our founders deliver on their boldest ambitions and turn their innovations into real-world impact at scale.
Combining data from different telescopes is one of the best ways to get a fuller picture of far-off objects. Because telescopes such as Hubble (visible light), the James Webb Space Telescope (infrared), and the Atacama Large Millimeter…
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
– RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers
NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors.
PD-1/VEGF-targeted bispecific antibodies represent a new class of cancer therapies that aim to help the immune system fight tumors more effectively and potentially overcome tumor resistance mechanisms by blocking both PD-1 and VEGF simultaneously. Additionally, given their potential to modulate both immune suppression and foster a favorable tumor microenvironment for antibody-drug conjugate (ADC) activity, PD-1/VEGF bispecific antibodies are also being explored in combination with ADCs. In early clinical studies, RC148 has shown initial favorable antitumor activity in combination with an ADC.
RC148 further strengthens AbbVie’s diverse oncology portfolio. In particular, it may offer new opportunities to explore combination regimens with AbbVie’s ADCs such as investigational telisotuzumab adizutecan (Temab-A), across multiple solid tumors with high unmet need including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
“Our partnership with RemeGen reflects AbbVie’s commitment to not only advance novel oncology treatments, but also to build strong collaborations with biopharmaceutical innovators globally as an increasingly important source of scientific and clinical progress,” said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology at AbbVie. “By combining the immune checkpoint inhibition and anti-angiogenic activity of RC148 together with the targeted cytotoxic activity of ADCs, we have the potential to identify meaningful options for patients across a range of solid tumors.”
“This collaboration is a significant milestone for RemeGen, highlighting the innovative potential of RC148 in addressing critical unmet medical needs in cancer treatment,” said Dr. Jianmin Fang, chief executive officer of RemeGen. “The deal further underscores RemeGen’s commitment to bringing cutting-edge therapies to patients worldwide. Working with AbbVie, we look forward to maximizing RC148’s clinical and commercial potential in China and globally.”
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize RC148 outside of the Greater China territory. RemeGen will receive an upfront payment of USD $650 million and is eligible to receive up to USD $4.95 billion in aggregate development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales outside the Greater China territory.
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
About RemeGen
RemeGen Co., Ltd. is a leading innovative biopharmaceutical company in China focused on the discovery, development, manufacturing and commercialization of proprietary biologics. The company is dual-listed on the Hong Kong Stock Exchange and the STAR Market of the Shanghai Stock Exchange.
RemeGen has built a highly differentiated pipeline across autoimmune, oncology and ophthalmology, with a proven ability to rapidly translate innovative science into clinically and commercially meaningful medicines. Its two flagship products, telitacicept and disitamab vedotin, have received approvals for a total of six indications in China, underscoring RemeGen’s strong capabilities in first-/best-in-class biologics discovery, efficient clinical execution and successful commercialization. Additional information is available on the company’s website at https://www.remegen.com/
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
SOURCE AbbVie